Weekly Rundown: Small-Cap Stocks with Upcoming Catalysts (May 27–30)

We've reviewed the latest filings and corporate updates to highlight the most noteworthy small-cap developments and investor events happening this week. Our aim is to keep you ahead of the curve with timely insights into emerging opportunities. Here’s what’s on our radar for the week of May 27 to May 30.

Companies Presenting at the 2025 ASCO Annual Meeting Watchlist (May 30 – June 3, Chicago, IL):

ALLO: June 1 – Oral on ALLO-316 + TIP poster on Phase 2 ALPHA3 trial.

KAPA: June 2 – Poster: "Effect of KROS 101 on immune cells".

IMMX: June 3 – Oral on NXC-201 by Dr. Heather Landau; KOL event at 3:00 PM.

IMNN: June 3 – Updated OVATION-2 Phase I/II survival data in ovarian cancer.

BCTX: June 2 – (3) posters + 1 publish-only abstract with positive survival data.

PDSB: June 2 – (3) abstracts on Versamune® HPV (PDS0101).

IPHA: May 31 & June 2 – 4 abstracts on Innate’s clinical-stage assets.

MAIA: May 31 – Poster on efficacy data from Phase 2 THIO-101 trial.

ANIX: June 2 – Phase 1: T-cell therapy targeting FSHR in recurrent OVCA.

INAB: May 30 – Oral: INB-200 γδ T cell therapy Phase 1 update for GBM.

AZTR: – Abstract on ATR04-484 Phase 1/2 EGFRi-related rash trial.

CERO: – Poster: First-in-human CER-1236 trial in AML (CertainT-1).

GNPX: May 31 – Phase 1/2: Gene therapy + atezolizumab in ES-SCLC.

KTTA: June 2 – Interim Phase 1 data for PAS-004 in MAPK-driven tumors.

ONCY: June 2 – Pelareorep role in PDAC anti-tumor immunity.

XLO: May 31 – Phase 2: Vilastobart + atezolizumab in MSS CRC.

MRSN: June 2 – Phase 1: Dose escalation for Emiltatug Ledadotin (Emi-Le).

ZNTL: May 31 – Poster on azenosertib combo in BRAF V600E mCRC.

CATX: May 30 & June 2 – [212Pb]VMT-α-NET & [212Pb]VMT01 data presentations.

ADAG: May 31 – Updated data on ADG126 in MSS CRC (no liver mets).

IMTX: May 31 & June 2 – IMA203 TCR T-cell therapy targeting PRAME.

AGEN: May 31 – BOT/BAL in MSS mCRC + pancreatic cancer trials-in-progress.

SLS: June 2 – Preclinical data for SLS009 in ASXL1-mutated CRC.

NUVB: May 31 – Additional results from TRUST-I & TRUST-II Phase 2 trials on taletrectinib for ROS1+ NSCLC.

BDSX: May 31 – Presentation: "Host immune classifier to predict survival with chemoimmunotherapy in PD-L1 ≥50% metastatic NSCLC."

PSNL: June 1 & 2 – Multiple presentations at ASCO on NeXT Personal® ctDNA assay data for residual and recurrent cancer detection.

IOVA: May 31 & June 2 – Presenting 5-year results from the C-144-01 trial of Amtagvi in advanced melanoma and a Trial-in-Progress poster for lifileucel + pembrolizumab in NSCLC at ASCO.

BCAB: June 2 – Poster at ASCO on Phase 2 trial of ozuriftamab vedotin (BA3021) in pretreated head and neck squamous cell carcinoma.

OABI: May 30–June 3 – Multiple partners to present data from programs using OmniAb technology at ASCO 2025.

Companies Presenting at the American Society of Clinical Psychopharmacology (ASCP) Conference (May 27–30, 2025, Scottsdale, AZ):

VTGN: May 28 & 29 – Posters on age of onset in SAD (fasedienol trials) and EGNR/EBG biomarkers for itruvone in MDD.

NLSP: May 29 – Preclinical data presentation on Mazindol ER.

ANRO: – Company expected to present.

RVPH: May 28 – Late-breaking poster on 12-month RECOVER extension trial for brilaroxazine in schizophrenia.

Companies Participating at Bitcoin 2025 (May 27–29, 2025, Las Vegas, NV):

FUFU: Sponsoring Bitcoin 2025. Charley Brady (VP IR) will speak on cloud mining in a featured session.

CIFR: Leadership team to participate in discussions on site capacity, growth strategy, Bitcoin mining, and HPC opportunities.

WULF: Senior management to participate in the upcoming conference.

BITF: Speakers include Ben Gagnon (CEO), Jeff Lucas (CFO), Alex Brammer (SVP, Mining Ops), Rachel Silverstein (General Counsel), and Tracy Krumme (SVP, IR & Comms).

AGRI: – CEO Jolie Kahn to speak on a panel: "Improving Mine Management Efficiency: How AI, Demand Response, and Heat Reuse Are Shaping Bitcoin."

Companies Participating at TD Cowen's 6th Annual Oncology Innovation Summit (May 27–28, 2025):

ALLO CHRS FHTX IOBT MRSN NUVB OLMA PMVP RLAY STRO TARA VIR WHWK ZNTL

Companies Participating at the 2025 Louisiana Energy Conference (May 27–29, 2025):

AMPY EPM PED

Companies Participating at the 22nd Annual Craig-Hallum Institutional Investor Conference (May 28, 2025):

BDSX CLOV DMAC LTRX NVTS PSNL RMNI RZLT SCPH SKYE

Companies Participating at the Lytham Partners Spring 2025 Investor Conference (May 29, 2025):

BANL DRTS FUFU MODD PYPD TTI UNCY

Companies Presenting at the Jefferies eVTOL / AAM Summit (May 28, 2025):

BLDE HOVR SRFM

Other Companies with Key Catalysts This Week:

WWR: May 27 – Investor call at 1:00 PM ET on Kellyton Graphite Plant, customer engagement, and secured debt financing.

ATYR: May 27 – Participating in Piper Sandler’s 3rd Annual Virtual Lung Symposium with ATS takeaways.

MIGI: May 27–30 – Participating in Web Summit.

SHLS: May 27 – Goldman Sachs Virtual Fireside Chat; May 28 – BofA Power, Utilities & Alt Energy Conference in NYC.

VMEO: May 29 – TD Cowen 53rd Annual Technology, Media & Telecom Conference.

OABI: May 29 – Benchmark 2025 Healthcare House Call Virtual Conference.

INBS: May 28–31 – All Rise Conference in FL, supporting U.S. partner SMARTOX and showcasing drug testing solution.

PRSO: May 28–30 – Attending Wireless Expo Japan at Tokyo Big Sight.

GRI: May 28 – CEO to participate in Virtual Investor Closing Bell Series at 4:00 PM ET.

HSDT: May 28–31 – Presenting MS therapy data at CMSC 2025 Annual Meeting, Phoenix.

AGL: May 28 – Bernstein 41st Strategic Decisions Conference; fireside chat at 4:30 PM ET.

MRKR: May 28 – CEO webcast: “Seven Years After FDA Approval – Have CD19 CAR-T Cells Met Expectations?” at 11:00 AM ET.

BIVI: May 28 – Virtual KOL event on Parkinson's disease at 12:00 PM ET.

DMAC: May 28 – Virtual KOL event at 8:00 AM ET on preeclampsia treatment landscape and Phase 2 design.

YMAB: May 28 – Virtual Radiopharmaceutical R&D update at 8:00 AM ET, including GD2-SADA clinical data and pipeline plans.

TBLA: May 28 – TD Cowen Technology, Media & Telecom Conference.

ATXS: May 31 – Presenting at the 14th C1 Inhibitor Deficiency & Angioedema Workshop in Budapest.

GIPR: By end of May / early June – Expected closure of two asset sales (Auburn & Tampa) to retire $10.7M in debt.

IFRX: Late May / early June – IDMC recommendation on Phase 3 trial interim analysis for vilobelimab in PG.

PALI: End of May – Topline data expected from Phase 1a study of PALI-2108 in ulcerative colitis.

CLSD: May 27 – Fireside chat at Stifel 2025 Virtual Ophthalmology Forum at 9:00 AM ET.

FTCI: May 28 – BofA Power, Utilities & Alt Energy Conference; in-person investor meetings.

IRD: May 29 – Presenting at Retinal Imaging Summit: “Using VR Guided Orientation Testing” at 9:00 AM ET.

IMUX: May 28–31 – CMSC 2025 Annual Meeting; presenting Nurr1 activator preclinical data, booth #911.

LMFA: May 28 – Orange Group & Blockware Conference in Las Vegas.

SGHT: May 27 – Presenting at Stifel 2025 Virtual Ophthalmology Forum.

UNIT: May 29 – Participating in Goldman Sachs 10th Annual Leveraged Finance & Credit Conference in Dana Point, CA.

SNTI: May 29 – CEO to present at Webull Biotech Investment Webinar.

RYAM: May 29 – KeyBanc Industrials & Basic Materials Conference; presented by Joshua Hicks.

EEX: May 29 – 1x1 investor meetings at Goldman Sachs 10th Annual Leveraged Finance Conference.

SGMT: May 29 – Hosting virtual KOL event on Phase 1 trial of denifanstat + resmetirom for MASH.

BEEP: May 29 – 1x1 investor meetings at Barrington Research Virtual Spring Investment Conference.

XTIA: May 29 – Hosting virtual Shareholder Town Hall at 4:15 PM ET.

--

Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTimePenny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.